1. Metabolic reprogramming to improve immunotherapy (R21)
NIH: National Cancer Institute, US and other funders
Closing Date 16 Feb 19
Funder’s Website Visit funder’s web page for this opportunity
The National Cancer Institute invites applications for its metabolic reprogramming to improve immunotherapy (R21) funding opportunity announcement. This announcement aims to generate a mechanistic understanding of the metabolic processes that support robust anti-tumor immune responses in vivo, determine how the metabolic landscape of the tumour microenvironment affects immune effector functions, and then use this information to manipulate the metabolic pathways used by the tumour, the immune response, or both to improve cancer immunotherapy. The objective of this call is to develop approaches to reprogramme the metabolic qualities of anti-tumour immune cells, either ex vivo or in vivo, to improve immunotherapy and approaches that target cancer cell metabolic pathways to impair cancer cell survival without compromising endogenous anti-tumour immunity.
This funding opportunity uses the NIH exploratory or developmental research (R21) grant mechanism and runs in parallel with one of identical scientific scope, PAR-16-228, which solicits applications under the NIH research project (R01) grant mechanism.
Eligible applicants include US and foreign for-profit or non-profit organisations and public or private institutions.
Application budgets are limited to US$275,000 over a maximum period of two years. No more than US$200,000 may be requested in any single year.
2. Examination of survivorship care planning efficacy and impact (R21 clinical trial optional)
NIH: National Cancer Institute, US and other funders
Closing Date 16 Feb 19
Funder’s Website
Visit funder’s web page for this opportunity
The National Cancer Institute invites applications for its examination of survivorship care planning efficacy and impact (R21 clinical trial optional) funding opportunity. This aims to stimulate research evaluating the effect of care planning on self-management of late effects of cancer therapy, with the goal to generate a body of science that will inform the development and delivery of interventions that improve follow-up care for cancer survivors. Specifically, this call aims to stimulate research that will:
- develop and test metrics for evaluating the impact of survivorship care planning;
- evaluate the impact of survivorship care planning on cancer survivors morbidity, self-management and adherence to care recommendations, utilisation of follow-up care;
- evaluate effects of planning on systems outcomes, such as associated costs and impact on providers and organisations implementing the care planning;
- identify models and processes of care that promote effective survivorship care planning.
This funding opportunity uses the NIH exploratory or developmental research (R21) grant mechanism and runs in parallel with one of identical scientific scope, PA-18-002, which solicits applications under the NIH research project (R01) grant mechanism.
US and foreign for-profit or non-profit organisations and public or private institutions may apply.
Application budgets are limited to USD 275,000 per year for a maximum project period of two years. No more than USD 200,000 may be requested in any single year.
3. Improving outcomes in cancer treatment-related cardiotoxicity (R21 clinical trial optional)
NIH: National Cancer Institute, US and other funders
Closing Date 16 Feb 19
Funder’s Website
Visit funder’s web page for this opportunity
The National Cancer Institute and the National Heart, Lung and Blood Institute invite applications for their improving outcomes in cancer treatment-related cardiotoxicity (R21: clinical trial optional) funding opportunity. This supports collaborative projects that contribute to the identification and characterisation of patients at risk of developing cancer treatment-related cardiotoxicity. The primary intent is to mitigate cardiovascular dysfunction while optimising cancer outcomes. The project must include methods that evaluate cardiac risk prior to treatment and integrate evidence-based cancer treatment regimens with screening, diagnostic and management strategies, including cytotoxic chemotherapies; targeted agents; immunomodulatory therapies; radiation that occur during cancer treatment or long-term survivorship.
This funding opportunity uses the NIH exploratory or developmental research (R21) grant mechanism and runs in parallel with one of identical scientific scope, PA-18-003, which solicits applications under the NIH research project (R01) grant mechanism.
US and foreign for-profit or non-profit organisations and public or private institutions may apply.
The total budget is worth up to USD 275,000 over a maximum period of two years. No more than USD 200,000 may be requested in any single year.
4. Neural regulation of cancer (R21)
NIH: National Cancer Institute, US and other funders
Closing Date 22 Feb 19
Funder’s Website
Visit funder’s web page for this opportunity
The National Cancer Institute invites applications for its neural regulation of cancer (R21) funding opportunity announcement. This announcement encourages collaborative, transdisciplinary research with both neuroscience and cancer elements, which together will advance current understanding of the nervous system contribution to cancer. Projects are expected to leverage current neuroscience expertise, experimental models, reagents and tools to address significant questions that advance our knowledge of cancer. Studies considered appropriate for this funding announcement include, but are not limited to, the following topics:
- advance current understanding of neural invasion in cancer progression and metastasis, the signalling networks that mediate this process and the consequences of inhibiting this process;
*help elucidate the mechanisms of neoneurogenesis in solid tumours, the molecules mediating this process and the impact on cancer progression when neoneurogenesis is inhibited;
- define the role of nerves in the tumour microenvironment that advance the understanding of the reciprocal cross-talk between nerves and the tumour or between nerves and other components of the tumour micro-environment that result in cancer progression and metastasis;
- build on current knowledge of the role of nerves in the bone marrow niche that promote the initiation and progression of hematologic malignancies and advance the understanding of cross-talk between the nerves and the cell components of the immune system;
- enhance the understanding of the influence of nerves on crucial cancer modulators including stem cells, blood vessels, immune surveillance and inflammation;
- elucidate the specific components of the nervous system that contribute to cancer processes, including the nerve types and neurotransmitters, neuropeptides or axon guidance molecules and the mechanisms that underlie their role in cancer;
- develop tools and protocols that enhance manipulation and analysis of tumour-associated nerves;
- determine if neural networks between normal and tumour tissue differ;
- include the identification or assessment of inhibitors or drugs used in neuroscience to determine their ability to prevent or treat cancer in a preclinical setting;
- investigating biobehavioural influences on cancer progression and metastasis and identification of the neural signalling pathways that mediate these influences on cancer.
This funding opportunity uses the NIH exploratory or developmental (R21) grant mechanism and runs in parallel with one of identical scientific scope, PA-16-245, which solicits applications under the NIH research (R01) grant mechanism.
US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply.
Application budgets are limited to US$275,000 over a two-year project period, with no more than US$200,000 in direct costs allowed in any year.
5. Capstone Editing grant for mid-career researchers
The Capstone Editing Grant for Mid-Career Researchers is currently open. Applications are open from 1 July to 30 December every year.
The Grant provides up to A$5,000 of seed funding for one researcher per year to undertake an innovative research project. The expectation is that the research project will gather preliminary data and lead to the development of a research council funding application.
The grant can be used to cover any costs related to the research project, such as software or small lab equipment; domestic or overseas travel to learn new techniques or collaborate with colleagues; academic editing of the grant proposal; and data analysis.
Capstone Editing defines a mid-career researcher as someone who 1) holds a PhD and 2) graduated from their PhD within the past five to ten years (excluding career interruptions in relation to caring responsibilities).
Application support and advice for the grant is available from Mary Lyons, Senior Research Grants Officer, Research Development and Support.
For further information, including eligibility and the online application process, please see the Capstone Editing website.